ISO/IEC 42001 explained: the AI management system standard for life sciences

Quick answer: What is ISO/IEC 42001?

ISO/IEC 42001 is the first international standard for establishing and continually improving an AI management system. For life sciences organizations, it provides a structured way to govern AI risks, responsibilities, documentation, and performance throughout the AI lifecycle—complementing existing frameworks such as GxP and ISO 13485 rather than replacing them.

Introduction

Most quality organizations in life sciences didn't choose to start managing AI, AI showed up inside systems they already had. A complaint platform added predictive triage. A document control tool started auto-classifying records. A manufacturing dashboard quietly began flagging anomalies using a model nobody in quality had signed off on.

Adoption happened at the feature level, not the strategy level, and most existing frameworks were never written with that scenario in mind. ISO 13485 tells you how to control a document. It doesn't tell you how to control a model that updates itself.

That's the gap ISO 42001 was built to close. Published in December 2023, it's the world's first international standard written specifically for managing AI, and it arrived close to the moment regulated industries needed it. It applies to any organization that develops, provides, or uses AI-based products or services, which now includes nearly every life sciences company running a modern QMS, whether or not that's been formally acknowledged.

This article covers what the standard actually requires, why it matters for regulated organizations specifically, and how it sits alongside the frameworks your quality team already knows.

Key takeaways

What is ISO/IEC 42001?

ISO 42001 specifies requirements for establishing, implementing, maintaining, and continually improving what the standard calls an AI Management System, or AIMS. It follows the same structural logic as ISO 9001 or ISO 13485, a management system standard, not a technical product standard, except the object being governed is AI itself. How it's developed, how it's deployed, how its risks are identified, and how its performance is monitored across its lifecycle.

That last point is worth sitting with. Regulations like the EU AI Act tell you what a compliant AI system needs to look like at a point in time. This standard tells you how your organization manages AI on an ongoing basis, applied continuously rather than validated once and left alone. Any organization can implement it, regardless of size, a five-person diagnostics startup and a multinational pharmaceutical manufacturer work from the same structural backbone, just at a different scale.

Why AI governance matters in life sciences

FDA's 2023 discussion papers on AI in drug development and manufacturing drew more than 800 public comments combined, on top of the agency's own experience reviewing hundreds of AI-component submissions in recent years. A peer-reviewed analysis of the manufacturing-specific feedback, co-authored by reviewers from FDA's CDER and CBER and published in AAPS Open, found that stakeholders are challenged by implementing AI in the pharmaceutical quality system, and separately face uncertainty managing AI models provided by third parties.

That's not an abstract governance concern. It's the exact gap this standard was written to close. Model documentation, third-party accountability, and lifecycle monitoring, applied specifically to a pharmaceutical quality system.

I saw a version of this firsthand two years ago, during a routine vendor requalification for a document control platform we'd used for years. Nothing dramatic, just the standard annual review. I asked our account rep for their model change control procedure, since a recent release note had mentioned smart classification for incoming records. There was a pause on the call. Then she asked me to repeat the question. Nobody on the vendor's side had been asked that before, not by us, not by any of their other pharma clients.

The feature had been live for months, and it wasn't bad faith, nobody had built the governance conversation around it yet, on either side of the contract. We wrote our own interim control while the vendor caught up. That exact gap is what a formal AIMS is designed to prevent from recurring.

Regulated industries need structured governance because AI behaves differently from the software quality teams have spent time learning to control. Traditional software is deterministic; validate it once, and it behaves the same way tomorrow. AI models drift and change behavior based on new data, so point-in-time validation alone doesn't provide the assurance a GxP environment requires.

Recommended learning:

QARA expert shares how to use AI in quality management and regulatory work

Key requirements of ISO 42001

The ISO 42001 standard organizes its requirements around a handful of pillars, familiar in shape to anyone who has implemented a management system before, applied here specifically to AI:

• Governance and leadership accountability: Top management defines AI policy, objectives, and ownership rather than leaving adoption to individual departments or IT alone.

• Roles and responsibilities: Clear accountability for who approves AI use, who monitors it, and who intervenes when something goes wrong.

• AI risk management: A structured process for identifying risks and opportunities across the AI lifecycle, from data sourcing through decommissioning.

• Documentation requirements: The same instinct that drives GxP documentation, extended to model decisions, training data provenance, and known limitations.

• Monitoring and performance evaluation: Ongoing assessment of whether a system still performs as intended, not a one-time sign-off.

• Continuous improvement: A feedback loop that captures incidents, near-misses, and performance drift, feeding them back into governance decisions.

None of this replaces the human judgment regulated quality work depends on. It gives that judgment somewhere structured to attach to.

How ISO 42001 fits into existing quality systems

This is usually the first question quality directors ask. Does this mean rebuilding the QMS? It doesn't. The standard is designed to sit alongside ISO 13485, GMP, and existing GxP frameworks rather than replace any part of them. If your quality system already governs documents, training, CAPA, and supplier qualification, an AIMS extends that same discipline to AI specifically, model documentation instead of just document control, model risk assessment instead of just process risk assessment, model monitoring instead of just periodic requalification.

Where an organization is already running ISO 13485, much of the underlying muscle memory transfers directly, writing a procedure, assigning an owner, running an internal audit. This framework asks you to point that same muscle at a new category of risk, not learn an entirely new discipline from scratch.

ISO 42001 and the EU AI Act

The relationship between these two is a common point of confusion, so it's worth being precise. The EU AI Act is a legal regulation with binding obligations, risk classifications, and penalties. This ISO 42001 standard, by contrast, is voluntary. They're not the same instrument, but they were built to work together. An organization managing its AI systems through a certified AIMS is, in practice, building most of the internal infrastructure the EU AI Act's high-risk provisions expect. Risk management, human oversight, logging, and documented governance. The ISO/IEC 42001 AI management system standard official documentation is explicit on this point, the framework is meant to complement sector regulation, not compete with it.

That alignment matters more now than a year ago. The EU AI Act's high-risk obligations, originally due August 2, 2026, were pushed back via the Digital Omnibus package finalized in June 2026, standalone high-risk systems now have until December 2, 2027, and high-risk AI embedded in regulated products, the category most relevant to medical devices, has until August 2, 2028. That's not a reason to slow down. It's extra runway, and organizations that use it to build real governance now, rather than waiting for the deadline to reappear, won't be rushing in 2027.

Recommended learning:

What Annex 22 means for AI governance in GMP-regulated environments

Who should implement ISO 42001?

In practice, this is relevant to a wider set of organizations than most people assume. ISO 42001 is a fit for:

• Medical device and diagnostics companies using AI in software-as-a-medical-device or in quality operations.

• Pharmaceutical and biotech manufacturers using AI for process monitoring, predictive quality, or supplier risk analysis.

• CROs and CDMOs deploying AI in data analysis or trial operations.

• Any organization purchasing eQMS, LIMS, or manufacturing execution software with embedded AI features, even without having built a model in-house.

That last category catches people off guard. You don't need to be building AI to need this, you need it the moment you're accountable for AI's output, and in a regulated industry, that accountability arrives whether or not you asked for it.

Conclusion

None of this arrived as a theoretical exercise. It arrived because regulated industries were already running AI inside their quality systems without a formal way to govern it, and auditors were starting to ask questions nobody had prepared answers for. Early adoption is about building the internal muscle that turns every future AI-related audit finding, warning letter, or EU AI Act assessment into a non-event.

Organizations that treat this framework as infrastructure, rather than paperwork, will look prepared while the rest of the industry is still catching up.The starting point is always the same. Know what's already running inside your quality system before you decide what to govern.

This is exactly where Scilife fits in. Scilife's eQMS gives quality and regulatory teams a single, connected place to manage documents, CAPAs, audits, and training; the same structures an AIMS builds on. When an AI feature gets added to your stack, having that traceability, ownership, and audit trail already in place means governing it properly, rather than reconstructing that history after the fact.

The starting point is always the same: know what's already running inside your quality system before you decide what to govern.

Scilife's eQMS gives quality and regulatory teams the connected document control, CAPA, and audit trail foundation that any future AI governance work will build on.